A Phase 3 interventional study of AMG 162 and Placebo in Prostate Cancer, sponsored by Amgen. Completed. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-17.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing denosumab in Prostatic Neoplasms — none open to participants now, none under way, none of them phase 3. Denosumab · Prostatic Neoplasms.
Among the 10 studies testing denosumab in Prostatic Neoplasms, this one has the largest enrollment, is the only one that started in 2004, is one of 8 in phase 3, and was the 1st registered.
7,053 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →None of the 10 studies testing denosumab in Prostatic Neoplasms is open now. The open studies under Prostatic Neoplasms, anywhere →
Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 1,233 Prostatic Neoplasms studies recruiting now, 931 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,468 is above the median of 60 across 5,354 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 324 across the 10 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 10 have an industry lead sponsor. The 4 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
23 studies in Prostatic Neoplasms by Amgen: 4 open now, 7 under way, 2 of them phase 3. Of 15 finished, 11 (73%) have results posted.
Among the 23 studies in Prostatic Neoplasms by Amgen, this one has the largest enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2004, is one of 9 in phase 3, and was the 3rd registered.
Amgen’s Prostatic Neoplasms studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing denosumab in Prostatic Neoplasms, from their registry updates:
Among Amgen’s 23 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study will evaluate AMG 162 in the treatment of bone loss in subjects undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer.
Other criteria also apply
Drug: AMG 162
Drug: Placebo
60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30
60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24
Lumbar Spine Bone Mineral Density Percent Chnage From Baseline at Month 24 Assessed by Dual Energy X-Ray Absorptiometry.
Time frame: 24 months
Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 24
Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 24 Assessed by Dual Energy X-Ray Absorptiometry.
Time frame: 24 months
Total Hip Bone Mineral Density Percent Change From Baseline at Month 24
Total Hip Bone Mineral Density Percent Change From Baseline at Month 24 Assessed by Dual Energy X-Ray Absorptiometry.
Time frame: 24 months
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36 Assessed by Dual Energy X-Ray Absorptiometry.
Time frame: 36 months
Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 36
Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 36 Assessed by Dual Energy X-Ray Absorptiometry.
Time frame: 36 months
Total Hip Bone Mineral Density Percent Change From Baseline at Month 36
Total Hip Bone Mineral Density Percent Change From Baseline at Month 36 Assessed by Dual Energy X-Ray Absorptiometry.
Time frame: 36 months
Number of Participants With Any Fracture Through Month 36
Any fracture includes osteroporotic fractures at any site excluding skull, facial, mandible, metacarpals, finger phalanges, and toe phalanges.
Time frame: 36 months
Number of Participants With a New Vertebral Fracture Through Month 36
New Vertebral Fracture Assessed by Lateral Spine X-ray using Genant Semiquantitative Scoring Method excluding any symptomatic new vertebral fracture associated with high trauma severity or a pathologic fracture.
Time frame: 36 months
Time to First Clinical Fracture Through Month 36
A clinical fracture was defined as any nonvertebral fracture or clinically evident fracture at the cervical vertebrae, thoracic vertebrae, and lumbar vertebrae that was associated with signs and/or symptoms indicative of a fracture. Fractures associated with high trauma severity and pathologic (ie, metastatic) fractures were excluded. Since the median time was not reached, time to first clinical fracture is represented by the Kaplan-Meier estimate of the percentage of participants with a clinical fracture.
Time frame: 36 months
Number of Participants With Any Fracture Through Month 24
Any fracture includes osteroporotic fractures at any site excluding skull, facial, mandible, metacarpals, finger phalanges, and toe phalanges.
Time frame: 24 months
First Subject Enrolled: 15-Apr-2004 Last Subject Enrolled: 29-Apr-2005
| Milestone | Placebo | Denosumab 60 mg Q6M |
|---|---|---|
| Started | 734 | 734 |
| Received study drug | 730 | 726 |
| Completed | 445 | 467 |
| Not completed | 289 | 267 |
| Withdrew: Physician decision | 4 | 2 |
| Withdrew: Adverse event | 23 | 29 |
| Withdrew: Withdrawal by subject | 143 | 127 |
| Withdrew: Death | 43 | 43 |
| Withdrew: Disease progression | 21 | 23 |
| Withdrew: Ineligibility determined | 8 | 10 |
| Withdrew: Lost to follow-up | 21 | 17 |
| Withdrew: Noncompliance | 7 | 3 |
| Withdrew: Other | 5 | 9 |
| Withdrew: Requirement for alternative therapy | 14 | 4 |
Lumbar Spine Bone Mineral Density Percent Chnage From Baseline at Month 24 Assessed by Dual Energy X-Ray Absorptiometry.
| Percent Change from Baseline | Placebo | Denosumab 60 mg Q6M |
|---|---|---|
| Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24 | -1 (-1.4 to -0.7) | 5.6 (5.3 to 5.9) |
Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 24 Assessed by Dual Energy X-Ray Absorptiometry.
| Percent Change from Baseline | Placebo | Denosumab 60 mg Q6M |
|---|---|---|
| Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 24 | -1.5 (-1.8 to -1.1) | 2.4 (2.1 to 2.8) |
Total Hip Bone Mineral Density Percent Change From Baseline at Month 24 Assessed by Dual Energy X-Ray Absorptiometry.
| Percent Change from Baseline | Placebo | Denosumab 60 mg Q6M |
|---|---|---|
| Total Hip Bone Mineral Density Percent Change From Baseline at Month 24 | -2 (-2.3 to -1.8) | 2.7 (2.5 to 3.0) |
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36 Assessed by Dual Energy X-Ray Absorptiometry.
| Percent Change from Baseline | Placebo | Denosumab 60 mg Q6M |
|---|---|---|
| Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36 | -1.2 (-1.5 to -0.8) | 6.8 (6.4 to 7.1) |
Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 36 Assessed by Dual Energy X-Ray Absorptiometry.
| Percent Change from Baseline | Placebo | Denosumab 60 mg Q6M |
|---|---|---|
| Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 36 | -1.8 (-2.2 to -1.5) | 3 (2.7 to 3.4) |
Total Hip Bone Mineral Density Percent Change From Baseline at Month 36 Assessed by Dual Energy X-Ray Absorptiometry.
| Percent Change from Baseline | Placebo | Denosumab 60 mg Q6M |
|---|---|---|
| Total Hip Bone Mineral Density Percent Change From Baseline at Month 36 | -2.6 (-2.8 to -2.3) | 3.2 (2.9 to 3.4) |
Any fracture includes osteroporotic fractures at any site excluding skull, facial, mandible, metacarpals, finger phalanges, and toe phalanges.
| Participants | Placebo | Denosumab 60 mg Q6M |
|---|---|---|
| Number of Participants With Any Fracture Through Month 36 | 53 | 38 |
New Vertebral Fracture Assessed by Lateral Spine X-ray using Genant Semiquantitative Scoring Method excluding any symptomatic new vertebral fracture associated with high trauma severity or a pathologic fracture.
| Participants | Placebo | Denosumab 60 mg Q6M |
|---|---|---|
| Number of Participants With a New Vertebral Fracture Through Month 36 | 26 | 10 |
A clinical fracture was defined as any nonvertebral fracture or clinically evident fracture at the cervical vertebrae, thoracic vertebrae, and lumbar vertebrae that was associated with signs and/or symptoms indicative of a fracture. Fractures associated with high trauma severity and pathologic (ie, metastatic) fractures were excluded. Since the median time was not reached, time to first clinical fracture is represented by the Kaplan-Meier estimate of the percentage of participants with a clinical fracture.
| Percentage of participants | Placebo | Denosumab 60 mg Q6M |
|---|---|---|
| Time to First Clinical Fracture Through Month 36 | 5.2 | 4.7 |
Any fracture includes osteroporotic fractures at any site excluding skull, facial, mandible, metacarpals, finger phalanges, and toe phalanges.
| Participants | Placebo | Denosumab 60 mg Q6M |
|---|---|---|
| Number of Participants With Any Fracture Through Month 24 | 45 | 32 |
Collected over 36 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 222/725 (30.6%) | 364/725 (50.2%) |
| Denosumab 60 mg Q6M | — | 253/731 (34.6%) | 390/731 (53.4%) |
| Event | Placebo | Denosumab 60 mg Q6M |
|---|---|---|
| Myocardial infarctionCardiac disorders | 18/725 | 14/731 |
| Cerebrovascular accidentNervous system disorders | 12/725 | 10/731 |
| Coronary artery diseaseCardiac disorders | 11/725 | 9/731 |
| PneumoniaInfections and infestations | 11/725 | 11/731 |
| Atrial fibrillationCardiac disorders | 8/725 | 11/731 |
| Cardiac failure congestiveCardiac disorders | 10/725 | 6/731 |
| Metastases to boneNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 10/725 | 3/731 |
| Transient ischaemic attackNervous system disorders | 4/725 | 9/731 |
| SyncopeNervous system disorders | 5/725 | 8/731 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/725 | 8/731 |
| Event | Placebo | Denosumab 60 mg Q6M |
|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 79/725 | 91/731 |
| Back painMusculoskeletal and connective tissue disorders | 73/725 | 79/731 |
| ConstipationGastrointestinal disorders | 74/725 | 73/731 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 51/725 | 66/731 |
| HypertensionVascular disorders | 47/725 | 54/731 |
| Oedema peripheralGeneral disorders | 47/725 | 52/731 |
| NasopharyngitisInfections and infestations | 45/725 | 47/731 |
| FatigueGeneral disorders | 45/725 | 44/731 |
| DizzinessNervous system disorders | 31/725 | 41/731 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 26/725 | 40/731 |
| Age, Continuous(Years) | Placebo | Denosumab 60 mg Q6M | Total |
|---|---|---|---|
| Mean | 75.5 ± 7.1 | 75.3 ± 7 | 75.4 ± 7.1 |
| Sex: Female, Male(Participants) | Placebo | Denosumab 60 mg Q6M | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 734 | 734 | 1468 |
| Race/Ethnicity, Customized(Participants) | Placebo | Denosumab 60 mg Q6M | Total |
|---|---|---|---|
| Asian | 3 | 5 | 8 |
| Japanese | 4 | 1 | 5 |
| American Indian or Alaska Native | 2 | 0 | 2 |
| Other | 3 | 0 | 3 |
| White or Caucasian | 609 | 615 | 1224 |
| Black or African American | 32 | 36 | 68 |
| Hispanic or Latino | 81 | 77 | 158 |
No study locations are listed for this record.
Ran from Aug 2004 to primary completion in May 2008, 45 months.
Results were first posted in Jun 2014, 6 years after primary completion. A results delay was requested in Nov 2009.
Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 45 months is above that.
Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab